<DOC>
	<DOCNO>NCT01034163</DOCNO>
	<brief_summary>The primary objective provide drug ongoing patient receive panobinostat characterize safety tolerability panobinostat patient HL achieve complete response follow autologous hematopoietic stem cell transplant ( AHSCT ) high dose chemotherapy ( HDT ) . Primary objective state reflect change original protocol amendment . The original objective longer feasible 41 367 patient randomize study halt due poor recruitment . An amendment write allow patient panobinostat continue treatment discontinuation/completion criterion meet ( patient unblinded ) . Therefore , study complete per amendment . No secondary objective include trial amendment ; change original protocol .</brief_summary>
	<brief_title>A Phase III Randomized , Double Blind , Placebo Controlled Multi-center Study Panobinostat Maintenance Response Patients With Hodgkin 's Lymphoma ( HL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Patient age great equal 18 year 2 . Patient history histologically confirm classical HL ( i.e . Nodular sclerosing ( NSHL ) , Mixedcellularity ( MCHL ) , Lymphocyterich ( LRHL ) , Lymphocyte deplete ( LDHL ) ) 3 . Patient achieve complete response CT/MRI scan within 9 week ( ± 1 week ) day first autologous peripheral blood/ bone marrow stem cell transfusion ( AHSCT ) follow HDT . Complete response define : Normalization node lesion compare pretransplant scan perform prior salvage therapy relapse . Any residual abnormal mass post transplant CT/MRI must metabolically inactive PET scan . 4 . Patient least one follow factor place risk relapse : Primary refractory disease ( include relapse ≤ 3 month completion 1st line treatment ) First relapse &gt; 3 &lt; 12 month last dose 1st line treatment Multiple relapse ( prior transplant ) Stage III/IV disease ( relapse , prior transplant ) Hemoglobin &lt; 10.5 gm/dL ( relapse , prior transplant ) Patient treat allogeneic transplant 2 . Patient receive antilymphoma therapy AHSCT include limited : chemotherapy prior start study biologic immunotherapy include monoclonal antibody experimental therapy prior start study radiation therapy 3 . Patient recover reversible toxicity due prior therapy ( e.g . return baseline Grade ≤1 ) except hematological laboratory parameter Note : Patient meet criterion toxicity stable irreversible , evidence panobinostat cause similar toxicity 4 . Patient receive prior treatment DAC inhibitor include panobinostat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phase III randomize</keyword>
	<keyword>double blind</keyword>
	<keyword>placebo control multi-center study</keyword>
	<keyword>panobinostat</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>risk relapse</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>